Abstract
Liver disease can present both with indolent or rapidly progressive disease. The liver plays a crucial role in regulating hemostasis through protein production, and different pathophysiological mechanisms form an underlying basis for bleeding in both acute and chronic liver disease. Acute liver failure features both synthetic dysfunction and high consumption. Chronic liver disease more frequently exhibits findings of synthetic dysfunction and vitamin K deficiency though can also include hyperfibrinolysis. Due to decreased liver production of both procoagulants and anticoagulants, synthetic dysfunction can create a precariously balanced hemostasis, and the predisposition toward bleeding may not be as prominent as some laboratory parameters may suggest. In liver disease, most laboratory measures of coagulation including prothrombin time (PT)/international normalized ratio (INR) are poor predictors of bleeding risk as they only effectively measure presence or loss of procoagulant factors of the extrinsic pathway. Viscoelastic testing such as ROTEM™ and TEG™ may be able to better model the in vivo clotting process and may help guide use of blood components and factor concentrates. Though rare, bleeding events in both chronic and acute liver disease can be catastrophic. Management of coagulopathy is essential both to prevent spontaneous bleeding and to protect patients when undergoing high-risk procedures, especially in the setting of acute bleeding. In the setting of variceal or upper gastrointestinal bleeds, medications such as octreotide, thrombopoietin agonists, and proton pump inhibitors may be needed as well. Invasive endoscopic treatments may be needed to treat gastrointestinal bleeds and varices either prophylactically or reactively. Interventional radiology, surgical procedures, and liver transplant can be considered in selected cases. Patients with acute and chronic liver disease present a complicated balance of coagulation, and careful monitoring is required to optimize outcomes. Vitamin K, fresh frozen plasma, cryoprecipitate, prothrombin complex concentrates, recombinant activated factor VII, platelets, and anti-fibrinolytics may be considered depending on the etiology and volume constrictions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015;2015:243–9.
Afdhal N, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000–7.
Tripodi A. Hemostasis in acute and chronic liver disease. Semin Liver Dis. 2017;37(1):28–32.
Lee WM. AASLD position paper: the management of acute liver failure: update. Hepatology. 2011;(55).
Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525–34.
Hernaez R, et al. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–53.
Narkewicz MR, et al. A learning collaborative approach increases specificity of diagnosis of acute liver failure in Pediatric patients. Clin Gastroenterol Hepatol. 2018;16(11):1801–10 e3.
Stravitz RT, et al. Bleeding complications in acute liver failure. Hepatology. 2018;67(5):1931–42.
Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis. 1996;16(4):403–14.
Pereira LM, et al. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut. 1992;33(1):98–102.
Boks AL, et al. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology. 1986;6(1):79–86.
Schiodt FV, et al. Thrombopoietin in acute liver failure. Hepatology. 2003;37(3):558–61.
Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis. 2009;13(1):95–107.
Blei AT, et al. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet. 1993;341(8838):157–8.
Pereira SP, et al. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol. 2005;42(3):365–70.
Sihler KC, Napolitano LM. Complications of massive transfusion. Chest. 2010;137(1):209–20.
Dirkmann D, et al. Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth Analg. 2008;106(6):1627–32.
Scott TR, et al. Pathophysiology of cerebral oedema in acute liver failure. World J Gastroenterol. 2013;19(48):9240–55.
Shah NL, et al. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol. 2014;11(11):675–82.
Caldwell SH. Management of coagulopathy in liver disease. Gastroenterol Hepatol (N Y). 2014;10(5):330–2.
Stravitz RT, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol. 2012;56(1):129–36.
Mallett SV, Chowdary P, Burroughs AK. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int. 2013;33(7):961–74.
Kuiper GJ, et al. Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity. Thromb J. 2016;14:1.
Heron M. Leading causes for 2016. Natl Vital Stat Rep. 2018;67(6).
Younossi ZM, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530 e1; quiz e60.
Lisman T, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44(1):53–61.
Roberts LN, Bernal W. Management of bleeding and thrombosis in critically ill patients with liver disease. Semin Thromb Hemost. 2015;41(5):520–6.
Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339(11):746–54.
Qureshi K, Patel S, Meillier A. The use of thrombopoietin receptor agonists for correction of thrombocytopenia prior to elective procedures in chronic liver diseases: review of current evidence. Int J Hepatol. 2016;2016:1802932.
Loffredo L, Violi F. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: a meta-analysis. Dig Liver Dis. 2019;51(1):24–7.
Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823–32.
Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol. 2013;11(9):1064–74.
de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167–76.
Garcia-Tsao G, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. 2007;102(9):2086–102.
Wikkelso A, et al. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev. 2016;(8):CD007871.
Barrera F, Zuniga P, Arrese M. Prediction of esophageal variceal bleeding in liver cirrhosis: is there a role for hemostatic factors? Semin Thromb Hemost. 2015;41(5):481–7.
Barclay SM, et al. Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease. Pharmacotherapy. 2013;33(4):375–82.
Reichert JA, Hlavinka PF, Stolzfus JC. Risk of hemorrhage in patients with chronic liver disease and coagulopathy receiving pharmacologic venous thromboembolism prophylaxis. Pharmacotherapy. 2014;34(10):1043–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Edwards, P.T., Miloh, T., Soundar, E.P., Teruya, J. (2021). Bleeding in Acute and Chronic Liver Disease. In: Teruya, J. (eds) Management of Bleeding Patients. Springer, Cham. https://doi.org/10.1007/978-3-030-56338-7_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-56338-7_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-56337-0
Online ISBN: 978-3-030-56338-7
eBook Packages: MedicineMedicine (R0)